Articles tagged "Immunosuppression"

2022 American Transplant Congress
Associations of Immunosuppression Regimen with Fracture Risk After Kidney Transplant in High-Risk Populations: Identifying Targets for Risk-Reduction
K. Lentine¹, S. Kupacchi², W. Cheungpasitporn³, R. Li⁴, Y. Caliskan⁴, M. Schnitzler⁴, M. McAdams-DeMarco⁵, J. Ahn⁵, S. Bae⁶, G. Hess⁷, D. Segev⁵, D. Axelrod²
¹Saint Louis University Center for Abdominal Transplantation, St. Louis, MO, ²U Iowa, Iowa City, IA, ³Mayo Clinic, Rochester, MN, ⁴Saint Louis University, Saint Louis, MO, ⁵Johns Hopkins, Baltimore, MD, ⁶Johns Hopkins, Baltimore, MO, ⁷Drexel, Philadelphia, MO
*Purpose: Disorders of bone and mineral metabolism frequently develop with advanced kidney disease, may be exacerbated by immunosuppression (ISx) after kidney transplant (KTx), and may…
2022 American Transplant Congress
Suppressive Effect of De Novo Everolimus on Primary Cytomegalovirus Infection in Kidney Transplant Recipient
S. Harada¹, H. Sasaki², Y. Takada², D. Takamoto², H. Harada², T. Hirano², H. Tanaka¹
¹Urology, Sapporo City General Hospital, Sapporo, Japan, ²Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan
*Purpose: It has been reported that everolimus (EVR) administration reduces the incidence of cytomegalovirus (CMV) infection, but clinical outcome in CMV-seronegative recipients with EVR-based regimen…
2022 American Transplant Congress
Outcomes in Lung Transplant Recipients Switched from Tacrolimus to Cyclosporine Due to Hyperammonemia Early Post-Transplantation
S. Goyal, J. Lyons, P. Stracener, B. Bemiss
Loyola University Medical Center, Chicago, IL
*Purpose: Assess the impact of switching from tacrolimus to cyclosporine due to hyperammonemia on outcomes at 1-year post-lung transplant.*Methods: A retrospective review of lung transplant…
2022 American Transplant Congress
Validation of the iBox Surrogate End Point in CNI Free, Belatacept Treated Patients (BENEFIT & BENEFIT-EXT)
G. Divard¹, O. Aubert¹, M. Raynaud¹, F. Vincenti², L. Rostaing³, A. Durbach⁴, C. Legendre¹, R. Vadanici⁵, A. Loupy¹, -. BENEFIT & BENEFIT-EXT Investigators⁶
¹Paris Transplant Group, INSERM, Paris, France, ²UCSF, San Francisco, CA, ³Grenoble, Grenoble, France, ⁴APHP, Paris, France, ⁵BMS, Rueil Malmaison, France, ⁶BMS, New York, NY
*Purpose: The iBox is a prognostication system for long-term kidney allograft survival, developed with mostly patients under a CNI based immunosuppression. Patients treated with a…
2022 American Transplant Congress
A Novel IL-2 Mutein Selectively Expands Regulatory T Cells and Prolongs Skin Graft Survival
O. Efe¹, T. J. Borges¹, R. B. Gassen¹, L. Morena¹, A. Al Jurdi¹, I. T. Lape¹, G. J. Bobcock², J. C. Madsen¹, L. V. Riella¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Charlestown, MA, ²Visterra, Inc., Waltham, MA
*Purpose: Promoting immune regulation through expansion of regulatory T cell (Treg) may allow immunosuppression minimization and improve long-term graft outcomes. Low-dose IL-2 is known to…
2022 American Transplant Congress
Pre-Transplant Vaccine Induced SARS-CoV-2 Antibodies Decrease Following Induction Therapy for Kidney Transplantation
N. Barros¹, A. C. Ermel¹, A. Sharfuddin², W. Goggins³, J. Fridell²
¹Indiana University, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN, ³Indiana University Hospital, Indianapolis, IN
*Purpose: Kidney transplant recipients (KT) and wait-listed individuals exhibit an impaired response to vaccinations. There is currently no data on the impact of induction immunosuppression…
2022 American Transplant Congress
The Role Of Gut Microbiome In Optimum Dose Selection Of Tacrolimus For Kidney Transplant Recipients
M. Nayebpour¹, N. Koizumi¹, J. Melancon²
¹George Mason University, Arlington, VA, ²George Washington University Hospital, Washington, DC
*Purpose: This study aims to validate and apply a personalized optimal dose selection model for Tacrolimus (Tac) for kidney transplant recipients at the George Washington…
2022 American Transplant Congress
Use of Belatacept in Non-Compliant Adolescent Patients
C. McAdams¹, C. Gluck¹, E. Hilmas²
¹Nemours Children's Health, Wilmington, DE, ²Nationwide Children's Hospital, Columbus, OH
*Purpose: Adolescents are at high risk for kidney transplant rejection due to non-compliance. While intravenous (IV) maintenance medications are FDA approved for adults, there is…
2022 American Transplant Congress
Pd-1 Licenses Activated Treg for Lymphatic Migration
W. Piao¹, L. Li¹, V. Saxena¹, K. Hippen², M. Shirkey¹, B. Blazar², I. Lape³, y. zhang³, J. Bromberg¹
¹Surgery, University of Maryland, Baltimore, MD, ²University of Minnesota, Minneapolis, MN, ³Harvard Medical School, Boston, MA
*Purpose: In addition to serving as fluid conduits, lymphatic vessels are critical portals for immune cell migration. Lymphatic endothelial cells (LECs) constitutively express high levels…
2022 American Transplant Congress
An Additional Dose Of Viral Vector Covid-19 Vaccine And Mrna Covid-19 Vaccine In Kidney Transplant Recipients: A Randomized Controlled Trial
J. Bruminhent¹, C. Setthaudom², P. Phornkittikorn³, P. Chaumdee³, S. Prasongtanakij⁴, S. Srisala⁴, K. Malathum¹, S. Boongird⁵, A. Nongnuch⁵, M. Assanatham⁵, S. Kiertiburanakul¹
¹Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ²Immunology Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ³Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁴Office of Research, Academic Affairs and Innovation, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁵Division of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
*Purpose: An additional dose of the COVID-19 vaccine following a primary series is recommended for solid organ transplant recipients. However, a comparison of the immunogenicity…